Skip to content

Search

Eli Lilly: upcoming dates · Chronopin

Chronopin
/
Companies
/
Eli Lilly

Eli Lilly: upcoming dates

Upcoming dates: 2 · All pins: 11

Next: Eli Lilly Q3 2026 Earnings Call, October 29, 2026.

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.

All Eli Lilly pins in search Wikipedia Website

Upcoming

Health09/23/2026@HealthDesk
Eli Lilly Q3 2026 Earnings Call
Eli Lilly and Company Corporate Center, East McCarty Street, Indianapolis, Indiana 46206, United StatesEli Lilly
Starts 10/29/2026 2:00PM UTCESTIMATEDDate confidence: ESTIMATEDA target, not a fixed dateHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all ESTIMATED pins71% CONFIDENCEOverall confidence: 71%How well the pin's source and references back up its dates.Weighted average of how firmly 6 references, the source included, support the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins from 50% to 74% confidencein 25 daysLilly has not confirmed the date yet (no "Lilly confirms date and conference call for third-quarter 2026" release as of 22 Sep 2026; the Q2 one came out on 22 July for 5 August). Public.com^[2] and Nasdaq^[3] list the Q3 report as "expected" on 10/29/2026 "before market open", matching Lilly's pattern (Q3 2025 reported October 30, 2025) and its calls, which "will begin at 10 a.m. Eastern time" - so 29 Oct 2026, 10:00 ET (14:00 UTC), estimated until Lilly's confirmation release.
Eli Lilly is expected to report third-quarter 2026 results on 29 October, with its usual 10 a.m. ET conference call. It goes in guiding to $85-87 billion of 2026 revenue after second-quarter revenue jumped 48% to $23.0 billion on Mounjaro and Zepbound.

Related tags

Health221
Lilly11
GLP-15
Obesity9
Foundayo3
Business508
Acquisition63
Finance332
FDA11
Science74
Earnings

Health09/23/2026@HealthDesk

Lilly Submits Retatrutide to the FDA for Approval

Eli Lilly and Company Corporate Center, East McCarty Street, Indianapolis, Indiana 46206, United States

Lilly Submits Retatrutide to the FDA for Approval

Lilly Submits Retatrutide to the FDA for Approval

Lilly Submits Retatrutide to the FDA for Approval

Starts 03/31/2027ESTIMATEDDate confidence: ESTIMATEDA target, not a fixed dateHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all ESTIMATED pins3 months late77% CONFIDENCEOverall confidence: 77%How well the pin's source and references back up its dates.Weighted average of how firmly 4 references, the source included, support the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins at 75% confidence or betterin 178 daysLilly "plans to subsequently submit retatrutide in Q1 2027 for U.S. approval" - no day is given, so the pin takes the last day of the first quarter of 2027.^[1]

Lilly plans to file its Biologics License Application for retatrutide, the triple-hormone obesity shot that cut weight by up to 28.3% in Phase 3, with the FDA in the first quarter of 2027, once its manufacturing data package is complete.

0

Recent

Health09/23/2026@HealthDesk
Lilly Presents eloraTZP Phase 2 Results at EASD 2026 in Milan
Allianz MiCo, Via Demetrio Stratos, Bolla, Milan, Lombardy 20149, ItalyEli Lilly
Starts 09/30/2026 2:30PM UTCSCHEDULEDDate confidence: SCHEDULEDGiven as scheduledHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all SCHEDULED pins86% CONFIDENCEOverall confidence: 86%How well the pin's source and references back up its dates.Weighted average of how firmly 3 references, the source included, support the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins at 75% confidence or better4 days agoLilly's release lists "EloraTZP symposium | Wednesday, September 30, 2026 | 4:30 to 5:30 p.m. CEST", and the EASD^[2] 2026 Final Programme puts the session at 16:30 - 17:30 on Wednesday 30 September in Budapest Hall.
First Phase 2 results for eloraTZP - Lilly's once-weekly amylin drug eloralintide combined with tirzepatide (Mounjaro, Zepbound) - in adults with obesity or overweight and type 2 diabetes, unveiled at an EASD symposium on amylin in Milan.
Health09/23/2026@HealthDesk
Lilly Breaks Ground on $6.5B Foundayo Plant in Houston's Generation Park
North Lake Houston Parkway, Generation Park, Harris County, Texas, 77050, United StatesEli Lilly
09/21/2026 - 12/31/2030ESTIMATEDDate confidence: ESTIMATEDA target, not a fixed dateHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all ESTIMATED pins77% CONFIDENCEOverall confidence: 77%How well the pin's source and references back up its dates.Weighted average of how firmly 6 references, the source included, support the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins at 75% confidence or better13 days agoLilly's release is datelined "HOUSTON^[4], Sept. 21, 2026" and says Lilly "broke ground today in Houston, Texas^[6]"; Community Impact^[2] reports the groundbreaking ceremony was held Sept. 21. Completion: CNBC^[3], 21 Sep 2026: Lilly "on Monday broke ground on the upcoming site nearly a year after first announcing it, and said it expects the plant to be operational by 2030"; Lilly's 23 Sep 2025 announcement said the site "is expected to be operational within five years".
A 236-acre plant that will make the active ingredient of Lilly's Foundayo weight-loss pill, with more than 600 permanent jobs and about 4,000 construction jobs. Lilly expects it running by 2030.
$6.5B
Health09/23/2026@HealthDesk
FDA Approves Lilly's Inluriyo With Verzenio for ESR1-Mutated Breast Cancer
Bowditch Road, Federal Research Center, Hillandale, Montgomery County, Maryland, 20993, United StatesEli Lilly
Starts 09/18/2026CONFIRMEDDate confidence: CONFIRMEDStated as firmHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all CONFIRMED pins85% CONFIDENCEOverall confidence: 85%How well the pin's source and references back up its dates.Weighted average of how firmly 5 references, the source included, support the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins at 75% confidence or better16 days agoLilly's release is datelined "INDIANAPOLIS, Sept. 18, 2026" and says it "announced today that the U.S. Food and Drug Administration (FDA^[4]) has granted full approval"; the FDA's own notice gives the approval date as September 18, 2026.
An all-oral pairing that doubled median progression-free survival to 11.1 months from 5.5 in ESR1-mutated patients in the EMBER-3 trial. It is Inluriyo's second FDA approval in under a year.
Health09/23/2026@HealthDesk
Lilly Agrees to Acquire Merida Biosciences for Up to $2.875 Billion
Eli Lilly and Company Corporate Center, East McCarty Street, Indianapolis, Indiana 46206, United StatesEli Lilly
Starts 08/31/2026CONFIRMEDDate confidence: CONFIRMEDStated as firmHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all CONFIRMED pins88% CONFIDENCEOverall confidence: 88%How well the pin's source and references back up its dates.Weighted average of how firmly 4 references, the source included, support the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins at 75% confidence or better34 days agoThe release is datelined "INDIANAPOLIS and CAMBRIDGE, Mass., Aug. 31, 2026" and says the companies "today announced a definitive agreement for Lilly to acquire Merida".^[1]
Lilly agrees to buy Merida Biosciences, whose Phase 1 MER511 is built to destroy the autoantibodies behind Graves' disease and thyroid eye disease, for up to $2.875 billion in cash.
$2.9B
Health09/23/2026@HealthDesk
Lilly Agrees to Buy Three Vaccine Developers for Up to $3.83 Billion
Eli Lilly and Company Corporate Center, East McCarty Street, Indianapolis, Indiana 46206, United StatesEli Lilly
Starts 05/26/2026CONFIRMEDDate confidence: CONFIRMEDStated as firmHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all CONFIRMED pins87% CONFIDENCEOverall confidence: 87%How well the pin's source and references back up its dates.Weighted average of how firmly 5 references, the source included, support the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins at 75% confidence or better131 days agoLilly's release is datelined "INDIANAPOLIS, May 26, 2026" and says Lilly "today announced agreements to acquire three companies".^[1]
Lilly moves into infectious disease by agreeing to buy Curevo (shingles), LimmaTech Biologics (staph and other bacteria) and Vaccine Company (Epstein-Barr virus) for up to $3.83 billion combined in cash.
$3.8B
Health09/23/2026@HealthDesk
Retatrutide Delivers 28.3% Weight Loss in Lilly's TRIUMPH-1 Phase 3 Trial
Eli Lilly and Company Corporate Center, East McCarty Street, Indianapolis, Indiana 46206, United StatesEli Lilly
Starts 05/21/2026CONFIRMEDDate confidence: CONFIRMEDStated as firmHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all CONFIRMED pins87% CONFIDENCEOverall confidence: 87%How well the pin's source and references back up its dates.Weighted average of how firmly 5 references, the source included, support the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins at 75% confidence or better136 days agoLilly's release is datelined "INDIANAPOLIS, May 21, 2026" and says the company "today announced positive topline results from TRIUMPH-1".^[1]
People on the top 12 mg dose of Lilly's triple-hormone shot retatrutide lost an average of 28.3% of their body weight (70.3 lbs) over 80 weeks, and 30.3% by two years in the extension - weight loss at the level of bariatric surgery.
Health09/20/2026@TechDesk
Lilly's Foundayo (Orforglipron) Weight-Loss Pill Approved by FDA
Indianapolis, IndianaEli Lilly
Starts 04/01/2026CONFIRMEDDate confidence: CONFIRMEDStated as firmHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all CONFIRMED pins85% CONFIDENCEOverall confidence: 85%How well the pin's source and references back up its dates.Weighted average of how firmly 4 references, the source included, support the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins at 75% confidence or better186 days agoLilly^[3] and the FDA^[4] approval letter date the approval April 1, 2026.
The FDA approved Eli Lilly's Foundayo, a once-daily GLP-1 pill for weight loss that needs no food or water restrictions, with direct-to-consumer sales from April 6.
Health09/23/2026@HealthDesk
Lilly Agrees to Acquire Centessa for Up to $7.8 Billion
Eli Lilly and Company Corporate Center, East McCarty Street, Indianapolis, Indiana 46206, United StatesEli Lilly
Starts 03/31/2026CONFIRMEDDate confidence: CONFIRMEDStated as firmHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all CONFIRMED pins87% CONFIDENCEOverall confidence: 87%How well the pin's source and references back up its dates.Weighted average of how firmly 6 references, the source included, support the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins at 75% confidence or better187 days agoThe joint release is datelined "INDIANAPOLIS and BOSTON and LONDON, March 31, 2026" and says the companies "today announced a definitive agreement for Lilly to acquire Centessa".^[1]
Lilly agrees to buy Centessa Pharmaceuticals, maker of the orexin agonist cleminorexton for narcolepsy, for $38 a share in cash (about $6.3 billion) plus a CVR worth up to $1.5 billion more; the deal closed on 24 June 2026.
$7.8B
Health09/23/2026@HealthDesk
Eli Lilly Becomes the First Drugmaker Worth $1 Trillion
Eli Lilly and Company Corporate Center, East McCarty Street, Indianapolis, Indiana 46206, United StatesEli Lilly
Starts 11/21/2025CONFIRMEDDate confidence: CONFIRMEDStated as firmHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all CONFIRMED pins87% CONFIDENCEOverall confidence: 87%How well the pin's source and references back up its dates.Weighted average of how firmly 5 references, the source included, support the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins at 75% confidence or better317 days agoBioPharma Dive^[1] (published Nov. 21, 2025): Lilly "on Friday briefly became the first drugmaker to reach $1 trillion in market value"; Reuters the same day: "Eli Lilly hit $1 trillion in market value on Friday". Nasdaq's^[4] daily prices show the 21 Nov close of $1,059.70 x 945,383,757 shares (10-Q cover) = $1.0018 trillion, and the 20 Nov high of $1,057.00 below the mark, so 21 Nov is the first day both intraday and at the close.
Eli Lilly's market value crossed $1 trillion on 21 November 2025, making it the first drugmaker and first health-care company to join the club dominated by tech giants. Its shares hit a record $1,066.65 and closed at $1,059.70, driven by Zepbound and Mounjaro.

214